CapTemY90 for Grade 2/3 NET Liver Metastases

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.

NCT Number	NCT04339036
Lead Sponsor	Abramson Cancer Center at Penn Medicine
Conditions	Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Enrollment	70 participants
Start Date	2021-10-07
Primary Completion	2028-07-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-04